Breaking News

INC Research Implements IAoCR Program

September 10, 2013

Becomes first global CRO to offer clinical research monitor credential

INC Research has become the first global CRO to implement the Clinical Research Monitor Accreditation program, an internationally recognized standard for competence in clinical research monitoring offered through the International Academy of Clinical Research (IAoCR). The new Clinical Credentialing program standardizes training of clinical research associates (CRAs) and establishes INC Research as the first accredited training center in the U.S.
 
IAoCR’s credentialing process focuses on independent verification of an individual’s ability to monitor clinical trials effectively in real-life situations. INC Research will train its CRAs, beginning with entry-level monitors, according to the new IAoCR program.
 
“INC Research is committed to providing the best clinical development services to our biopharmaceutical partners, including the most highly trained and competent monitoring staff in the industry,” said Alistair Macdonald, chief operating officer. “The Clinical Credential program will validate INC Research monitors' capabilities against globally recognized best practices, including recognition and reporting of adverse events, understanding regulatory processes, preparing for successful site initiations and site visits and more. Customers can therefore be confident the CRAs assigned to their studies are not only well trained and field tested, but also that their skills have been certified against an independent quality standard.”
 
“Competent monitors play an essential role in getting new treatments to market faster while protecting the rights and wellbeing of patients involved in clinical trials,” said Jacqueline Johnson North, chief executive officer of IAoCR. “That’s why offering programs that regulate and standardize training for CRAs is so important. I commend INC Research for being the first global CRO to embrace this program.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research